CClinicalTrials.gg
Active, not recruitingNCT06956131Updated Feb 17, 2026

Metabolite Changes Following Consumption Of Different Protein Drinks In Singapore Older Adults

An interventional study of Casein Protein Isolate Drink and Whey Protein Isolate Drink in Aging and Protein Metabolism, sponsored by National University of Singapore. Active, not recruiting at 1 site in Singapore. Open to participants aged 60 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by National University of Singapore · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
60 Years to 80 Years
Sex
All
01

Study summary

The study aims to investigate the acute effects of different protein sources (i.e., casein, whey, soy) on metabolomic profiles (e.g., amino acids in the blood), along with other outcomes such as cognitive function, mood, and appetite. While the study does not directly aim to prevent, prognosticate, diagnose, or alleviate any disease, it may provide insights that could inform dietary recommendations and support disease prevention efforts in older adults.

Read the detailed description

This study will be a double-blind, randomised, placebo-controlled trial using a crossover study design. 25 older adults (aged 60 to 80) will be recruited and assigned to consume 4 different test drinks in a random order on 4 different visits. This study aims to investigate whether higher protein consumption of different sources will influence postprandial plasma and urinary metabolomic profiles, cognition, mood and appetite. The study will comprise 1 screening visit and 4 test visits separated separated by a minimum washout period of >7 days

02

Conditions studied

  • Aging
  • Protein Metabolism

Keywords

  • Older adults
  • Metabolomics
  • Protein intake
  • Protein metabolism
  • Acute
  • Postprandial
  • Cognitive function
  • Mood
  • Appetite
03

In context

Lead sponsor

National University of Singapore is the lead sponsor of 206 studies on the registry; 52 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • English-literate and able to give informed consent
  • Adults 60 to 80 years old (inclusive)
  • (If applicable) Postmenopausal
  • BMI of 18·5 to 30 kg/m2 (inclusive)

Exclusion criteria

Exclusion Criteria:

  • Currently participating in another clinical study that involves altering the regular diet and/or involves consuming a dietary supplement or investigated food product as an intervention
  • Weight change >3 kg in the past 3 months
  • Exercising vigorously over the past 3 months (i.e., engaging in high-intensity exercises for more than 3 hours a week, where high-intensity exercises leave one out of breath and unable to talk or sing during the workout)
  • Current smokers or have quit smoking for less than 5 years
  • Drinking >2 alcoholic drinks per day (i.e., one drink is defined as either 150 ml of wine, 340 ml of beer/cider or 45 ml of distilled spirit)
  • If drinking ≤2 alcoholic drinks per day, not willing to stop consumption of alcoholic beverages two days before and on the day of the test visits (total 12 days)
  • Not willing to stop consumption of caffeinated beverages 10 to 12 hours before and on the day of the test visits (total 4 days)
  • Taking supplements containing omega-3, magnesium, gamma-aminobutyric acid (GABA), L-theanine, melatonin and/or 5-hydroxytryptophan for the past 3 months, and not willing to discontinue usage 3 months before and during the study duration
  • Currently on a specialised diet (e.g., vegetarian, vegan, weight loss diet)

    • Had serious food allergies in the past, or having intolerance, sensitivities or allergies to any of the following: milk/dairy products (e.g., casein, whey), starch/starch-derived products (e.g., rice, corn, wheat, potato), soy/soy-derived products, gluten, eggs, nuts, peanuts, fish and crustaceans.
  • Disease or impairment of the kidney and/or liver
  • Currently diagnosed with diabetes, sleep disorders, gastrointestinal issues (e.g., lactose intolerance, irritable bowel syndrome), gout and/or G6PD deficiency
  • History of diseases known to affect the central nervous system (e.g., heart disease, stroke, migraine headaches, multiple sclerosis, Parkinson's disease, mental illnesses)
  • Taking antibiotics 2 weeks prior to study participation
  • Taking medication known to interfere with cognitive function and mental wellbeing (e.g., benzodiazepines, antidepressants, other central nervous agents)
  • Taking anti-hypertensive or cholesterol-lowering drugs for less than 3 years unless medically declared by an official doctor to be in stable condition
  • Poor peripheral venous access based on past experiences with blood drawing
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Casein Protein Drink

    30 g protein equivalent of casein protein isolate dissolved in \~250 mL of water

    Dietary Supplement: Casein Protein Isolate Drink

  • Experimental
    Whey Protein Drink

    30 g protein equivalent of whey protein isolate dissolved in \~250 mL of water

    Dietary Supplement: Whey Protein Isolate Drink

  • Experimental
    Soy Protein Drink

    30 g protein equivalent of soy protein isolate dissolved in \~250 mL of water

    Dietary Supplement: Soy Protein Isolate Drink

  • Placebo comparator
    Maltodextrin Drink

    30 g carbohydrate equivalent of maltodextrin powder dissolved in \~250 mL of water

    Dietary Supplement: Maltodextrin Drink

Interventions

  • Dietary supplementCasein Protein Isolate Drink

    30 g protein equivalent of casein protein isolate dissolved in \~250 mL of water

  • Dietary supplementWhey Protein Isolate Drink

    30 g protein equivalent of whey protein isolate dissolved in \~250 mL of water

  • Dietary supplementSoy Protein Isolate Drink

    30 g protein equivalent of soy protein isolate dissolved in \~250 mL of water

  • Dietary supplementMaltodextrin Drink

    30 g carbohydrate equivalent of maltodextrin powder dissolved in \~250 mL of water

06

What researchers measure

Primary outcomes

  1. Changes in metabolites found in plasma (plasma metabolomics)

    Untargeted metabolomics profiling of plasma will be conducted using ultra performance liquid chromatography-quadrupole time of flight-mass spectrometry (UPLC-QTOF-MS)

    Time frame: Baseline, 15, 30, 60, 90, 120, 180, 240, 300 minutes

  2. Changes in metabolites found in urine (urinary metabolomics)

    Untargeted metabolomics profiling of urine will be conducted using ultra performance liquid chromatography-quadrupole time of flight-mass spectrometry (UPLC-QTOF-MS)

    Time frame: Baseline, 60, 120, 180, 240, 300 minutes

Secondary outcomes

  1. Cognitive Function

    The Computerised Mental Performance Assessment System (COMPASS) will be administered via a laptop. The COMPASS tests consist of 5 consecutive tests, including Digit Vigilance, Stroop, Rapid Visual Information Processing, Computerised Corsi Blocks Lite, Alphabetic Working Memory and Serial Subtraction, where the correctness and reaction time will be recorded. The test is expected to take around 15 minutes.

    Time frame: Baseline, 15, 60, 120, 180, 240, 300 minutes

  2. Mood

    The Profile of Mood States (POMS) questionnaire will be administered, which contains various words that describe feelings. Participants will indicate, for each word, how they currently feel on scale of 0 (Not at all) to 4 (Extremely).

    Time frame: Baseline, 15, 60, 120, 180, 240, 300 minutes

07

Study locations

1 site
  • NUS, Department of Food Science and Technology, 1 Science Drive 3, Block S13, #03-07
    Singapore, 117550, Singapore
08

References and documents

Publications

  • Lanng SK, Oxfeldt M, Johansen FT, Risikesan J, Hansen M, Bertram HC. Acute changes in the metabolome following resistance exercise combined with intake of different protein sources (cricket, pea, whey). Metabolomics. 2023 Nov 24;19(12):98. doi: 10.1007/s11306-023-02064-0. PubMed 37999866 ↗

Individual participant data

Plan to share: No — Electronic copies of the data with identifiable participant information will be kept on NUS OneDrive with access limited only Dr Kim Jung Eun and her research staff. All data will be de-identified prior to statistical analyses.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06956131
Lead sponsor
National University of Singapore
Collaborators
Bezos Earth Fund
Responsible party
Jung Eun Kim (Assistant Professor, National University of Singapore) — Principal investigator
First posted
May 2, 2025
Start date
May 20, 2025
Primary completion
Feb 9, 2026
Completion
Dec 2026 (estimated)
Last update
Feb 17, 2026

Study contacts

Jung Eun Kim, Ph.D., R.D.
principal investigator · National University of Singapore, Department of Food Science and Technology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion